Press release
Plaque Psoriasis Clinical Market Projected to Reach USD 27.6 Billion by 2034
Plaque Psoriasis Clinical
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/73631
Over the past decade, advancements in biologic and targeted small molecule therapies have revolutionized psoriasis management. From TNF-α inhibitors to IL-17 and IL-23 inhibitors, treatment options have expanded significantly, providing long-term control and improved quality of life. The global plaque psoriasis clinical market continues to evolve, fueled by ongoing research, expanding biologic portfolios, and increasing access to personalized dermatology care.
Market Overview
• Market Size (2024): USD 11.5 billion (estimated)
• Forecast (2034): USD 27.6 billion
• CAGR (2024-2034): ~9.2%
Key Growth Drivers:
• Rising prevalence of psoriasis, particularly in developed and industrialized nations.
• Growing availability and adoption of biologic and biosimilar therapies.
• Expanding clinical research into novel immune targets and oral small molecules.
• Increasing patient awareness and demand for effective, long-term management.
Challenges:
• High treatment costs of biologic drugs.
• Limited access to advanced therapies in developing regions.
• Psychological burden and stigma impacting patient adherence.
Leading Companies:
AbbVie Inc., Novartis AG, Eli Lilly and Company, Amgen Inc., Johnson & Johnson, Bristol Myers Squibb, UCB Pharma, Pfizer Inc., Leo Pharma A/S, Sun Pharmaceutical Industries Ltd.
Segmentation Analysis
By Treatment Type
• Biologics (TNF Inhibitors, IL-17 Inhibitors, IL-12/23 Inhibitors, IL-23 Inhibitors)
• Small Molecule Drugs (Apremilast, JAK Inhibitors, PDE4 Inhibitors)
• Topical Therapies (Corticosteroids, Vitamin D Analogs, Calcineurin Inhibitors)
• Phototherapy
• Others (Combination & Novel Therapies)
By Route of Administration
• Oral
• Injectable
• Topical
By Severity Level
• Mild
• Moderate
• Severe
By End User
• Hospitals & Dermatology Clinics
• Specialty Pharmacies
• Research & Academic Institutes
Summary:
Biologic therapies dominate the market, accounting for the largest revenue share due to their high efficacy and durable response rates. IL-17 and IL-23 inhibitors represent the fastest-growing class, while oral small molecules are gaining traction for their ease of use. Topical and phototherapy treatments remain preferred for mild cases, especially in primary care settings.
Explore Full Report here: https://exactitudeconsultancy.com/reports/73631/plaque-psoriasis-psoriasis-vulgaris-clinical-market
Regional Analysis
North America
• Largest market share in 2024 due to high diagnosis rates, advanced healthcare infrastructure, and strong reimbursement frameworks.
• Major contribution from the U.S., supported by new biologic approvals and patient access programs.
Europe
• Significant market presence with robust adoption in Germany, the UK, France, and the Nordic countries.
• EMA support for biosimilars driving affordability and wider access.
Asia-Pacific
• Fastest-growing region (CAGR ~10.5%) driven by rising prevalence, improving healthcare infrastructure, and growing access to branded and biosimilar biologics.
• China, Japan, and India emerging as key growth markets.
Middle East & Africa
• Early-stage adoption of biologics, primarily in GCC nations due to strong healthcare investments.
• Limited access to advanced treatments in developing sub-regions.
Latin America
• Moderate growth, led by Brazil and Mexico through public health initiatives and expanding dermatology networks.
Summary:
While North America and Europe dominate, Asia-Pacific is poised for the fastest growth, supported by biosimilar expansion, dermatology awareness, and increasing investment in specialty care.
Market Dynamics
Key Growth Drivers
• Expanding portfolio of next-generation biologics targeting IL-23 and IL-17 pathways.
• Increasing R&D in oral small molecules and JAK inhibitors.
• Wider use of digital dermatology tools and teledermatology consultations.
• Government initiatives promoting chronic disease awareness and treatment accessibility.
Key Challenges
• Affordability barriers in low- and middle-income countries.
• Long-term safety and efficacy monitoring of novel biologics.
• Patient non-compliance due to chronic disease fatigue or side effects.
Latest Trends
• Rise of biosimilar competition enhancing cost-effectiveness and accessibility.
• Integration of AI-based imaging and digital diagnostics in clinical dermatology.
• Increasing research into microbiome-targeted therapies and RNA-based treatments.
• Emergence of personalized and precision dermatology guided by genomic data.
Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=73631
Competitor Analysis
Major Players:
• AbbVie Inc.
• Novartis AG
• Eli Lilly and Company
• Amgen Inc.
• Johnson & Johnson
• Bristol Myers Squibb
• UCB Pharma
• Pfizer Inc.
• Leo Pharma A/S
• Sun Pharmaceutical Industries Ltd.
Competitive Landscape:
The market is highly competitive and innovation-driven, dominated by companies like AbbVie (Skyrizi, Humira), Novartis (Cosentyx), and Eli Lilly (Taltz). The shift from TNF inhibitors to IL-17/23 pathway inhibitors marks a major therapeutic transition. Biosimilars and small molecules are intensifying competition by offering cost-effective alternatives. Strategic mergers, partnerships, and pipeline expansions are central to maintaining leadership in this evolving field.
Conclusion
The plaque psoriasis (psoriasis vulgaris) clinical market is projected to grow from USD 11.5 billion in 2024 to USD 27.6 billion by 2034, at a CAGR of 9.2%. Fueled by advancements in biologic and small-molecule therapies, increased disease awareness, and expanding healthcare access, the market is on a strong upward trajectory.
Despite cost and access barriers, ongoing R&D in targeted immunotherapies, AI-assisted dermatology, and biosimilars ensures continued innovation. With Asia-Pacific emerging as a high-growth region and biologics evolving toward higher precision and safety, the global outlook remains highly positive.
Key Takeaway: Companies that invest in next-generation biologics, biosimilar expansion, and digital dermatology innovations will lead the transformation of chronic skin disease management through 2034.
This report is also available in the following languages : Japanese (尋常性乾癬(尋常性乾癬)臨床), Korean (플라크 건선(Psoriasis Vulgaris) 임상), Chinese (斑块状银屑病(寻常型银屑病)临床), French (Psoriasis en plaques (psoriasis vulgaire) clinique), German (Plaque-Psoriasis (Psoriasis vulgaris) Klinisch), and Italian (Psoriasi a placche (psoriasi volgare) clinica), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/73631/plaque-psoriasis-psoriasis-vulgaris-clinical-market#request-a-sample
Our More Reports:
Solar Aluminum Alloy Frame Market
https://exactitudeconsultancy.com/reports/75231/solar-aluminum-alloy-frame-market
Photovoltaic Panel Aluminum Frame Market
https://exactitudeconsultancy.com/reports/75232/photovoltaic-panel-aluminum-frame-market
Healthcare AI Computer Vision Market
https://exactitudeconsultancy.com/reports/75233/healthcare-ai-computer-vision-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Plaque Psoriasis Clinical Market Projected to Reach USD 27.6 Billion by 2034 here
News-ID: 4209893 • Views: …
More Releases from Exactitude Consultancy
Tension Control Clutch Market USD 1.12B in 2024, Projected USD 2.14B by 2034, CA …
Introduction
As global industries continue to advance toward automation and precision control, tension control clutches have become indispensable components in modern production systems. These clutches regulate torque and web tension in applications such as printing, packaging, converting, wire winding, textile, and paper manufacturing, ensuring smooth material handling, reduced waste, and high-quality output.
According to Exactitude Consultancy, the global tension control clutch market was valued at USD 1.12 billion in 2024 and is…
Inflammatory Bowel Disease (IBD) Clinical Market Projected to Reach USD 50.9 Bil …
Inflammatory Bowel Disease (IBD), encompassing Crohn's disease and ulcerative colitis, is a chronic inflammatory condition of the gastrointestinal tract that affects millions worldwide. IBD is driven by immune dysregulation, genetic predisposition, and environmental triggers, leading to severe abdominal pain, diarrhea, weight loss, and reduced quality of life.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/73633
Over the past two decades, biologic therapies have transformed IBD management by targeting specific immune…
Rhabdomyosarcoma Clinical Market Projected to Reach USD 392 Million by 2034
Rhabdomyosarcoma (RMS) is a rare and aggressive malignant tumor that arises from skeletal muscle progenitor cells, primarily affecting children and adolescents. Representing the most common soft tissue sarcoma in pediatric populations, RMS accounts for approximately 3-4% of all childhood cancers. Despite advancements in multimodal therapy-including surgery, chemotherapy, and radiation-recurrence and metastasis remain major clinical challenges.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/73635
Driven by advances in molecular diagnostics, targeted…
Medical Smart Drug Cabinet Market USD 1.36B in 2024, Projected USD 3.42B by 2034 …
Introduction
In an era of growing healthcare digitalization, medical smart drug cabinets have become critical components of hospital infrastructure. These intelligent storage systems combine automation, inventory management, and data analytics to ensure the safe, accurate, and efficient handling of pharmaceuticals and medical supplies. Designed for hospitals, pharmacies, and clinics, they enhance medication security, prevent human error, and improve regulatory compliance.
According to Exactitude Consultancy, the global medical smart drug cabinet market was…
More Releases for Psoriasi
Psoriasis Patient Pool Analysis Market Forecast to Reach USD 32.5 Billion by 203 …
Psoriasis is a chronic, immune-mediated skin condition characterized by red, scaly plaques that significantly affect patients' physical and emotional well-being. Beyond the skin, psoriasis is linked to systemic comorbidities such as psoriatic arthritis, cardiovascular disease, and depression. With millions affected globally, psoriasis remains a major public health issue.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71525
The psoriasis patient pool is steadily expanding due to rising diagnosis rates, better awareness…
Generalized Pustular Psoriasis (GPP) Market is expected to reach USD 3.1 billion …
Generalized pustular psoriasis (GPP) is a rare, severe, and potentially life-threatening form of psoriasis characterized by widespread sterile pustules, systemic inflammation, and recurrent flares. Unlike plaque psoriasis, GPP can cause acute episodes that require emergency care, making it a critical unmet need in dermatology.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71539
Until recently, treatment options for GPP were limited to off-label use of systemic therapies and immunosuppressants. However, the…
Phototherapies for Psoriasis Market Set to Witness Significant Growth by 2025-20 …
Introduction
Psoriasis is a chronic autoimmune skin condition characterized by rapid skin cell turnover, leading to scaling, inflammation, and plaques. Affecting millions globally, psoriasis is not only a dermatological concern but also a systemic disorder linked to comorbidities such as arthritis, cardiovascular disease, and metabolic syndrome.
Phototherapy has long been an established treatment option for moderate-to-severe psoriasis, leveraging controlled ultraviolet (UV) light to slow skin cell growth and reduce inflammation. Recent advancements…
Chronic Plaque Psoriasis Market is expected to double, reaching USD 36 billion b …
Chronic plaque psoriasis is the most common form of psoriasis, accounting for nearly 80-90% of all cases worldwide. It is a chronic autoimmune disease characterized by raised, inflamed, and scaly skin patches that significantly affect patients' quality of life. While topical therapies and phototherapy have long been standard treatments, the advent of biologics and targeted small molecules has transformed the market.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71377
With…
Generalized Pustular Psoriasis (GPP) Market Emerging Trends and Growth Prospects …
Introduction
Generalized pustular psoriasis (GPP) is a rare, severe, and potentially life-threatening form of psoriasis characterized by widespread pustules, systemic inflammation, and recurrent flares. Unlike plaque psoriasis, GPP is less common but often far more severe, requiring urgent treatment and long-term disease management.
With increasing awareness, advances in biologics, and the emergence of targeted therapies specifically developed for GPP, the global market is entering a transformative phase. Over the next decade, pharmaceutical…
Moderate to Severe Psoriasis Market Growth, Trends, Consumer Demand and Key Oppo …
Introduction
Psoriasis is a chronic, immune-mediated skin disorder marked by red, scaly plaques that can cause significant physical discomfort and psychological burden. Among the different types, moderate to severe psoriasis requires systemic therapy or biologics due to its extensive nature and comorbidities, such as psoriatic arthritis, cardiovascular disease, and metabolic syndrome.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71343
Historically, management involved topical corticosteroids, phototherapy, and systemic drugs like methotrexate or…
